Open, controlled, randomized and multicenter study comparing the efficacy and safety of repeated slow intravenous infusions of 2 doses of doxorubicin Transdrug (DT) (20 mg / rrr 'or 30 mg / rrr') with those of the reference improvement treatment (MRT) ) in patients with advanced hepatocellular carcinoma (HCC) after failure or intolerance to sorafenib. 'ReLive Study'
BA2011/03/04
Code
BA2011/03/04
Promoter
BioAlliance Pharma, 49 boulevard du General Martial Valin, 75015 París, Francia.
Pathology and candidate patients
Advanced hepatocellular carcinoma. Patients with advanced hepatocellular carcinoma, in those who have failed or have not tolerated treatment with sorafenib.
Medical equipment
Dr. Manuel Sureda González
Plataforma Oncología. Hospital Quirónsalud Torrevieja.
Study status
Active. Start date 29/10/2013
Test product
Doxorubicina Trandrug
Date CEIC
14/05/2013
CEIC
Comité Ético de Investigación Clínica Regional de la Comunidad de Madrid.
Contact
If you are interested in this clinical trial because you believe that you or a family member of yours can benefit from this new treatment. You can request a consultation with the responsible specialist in our center [Dr. Manuel Sureda González] sending an email to the address: manuel.sureda@quironsalud.es
